ReviewDiscover oncology2026
Antitumor effect of dipyridamole mediated by inhibiting the interaction between platelets and tumor cells.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dipyridamole is a well-known antithrombotic and a vasodilator. It is used to treat cerebrovascular and cardiovascular diseases owing to its antiplatelet effects. Platelets play a key role in thrombosis and hemostasis, and after cancer cells enter the bloodstream, they interact with these cells to protect them and promote metastasis. Dipyridamole inhibits tumor progression by blocking platelet aggregation and platelet-mediated Epithelial-to-mesenchymal transition (EMT) via targeting the extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinases (MAPK) signaling pathway, further highlighting its potential antitumor properties. However, studies on the anti-tumor mechanisms of dipyridamole are currently limited and incomplete. In this review, we summarize the pathways through which dipyridamole disrupts platelet-tumor cell interactions and exerts antitumor effects, aiming to inform the development of novel anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.